{
    "info": {
        "nct_id": "NCT04669067",
        "official_title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)",
        "inclusion_criteria": "* TP53 wildtype AML\n* Relapsed/Refractory to at least one prior therapy, one of which must have included a FLT-3 inhibitor\n* FLT3 mutation (FLT3-TKD or FLT3-ITD)\n* ECOG 0-2\n* Adequate hematologic, hepatic, and renal functions\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* AML subtype 3\n* Prior treatment with MDM2 antagonist therapies\n* Eligible for HSCT",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* TP53 wildtype AML",
            "criterions": [
                {
                    "exact_snippets": "TP53 wildtype AML",
                    "criterion": "TP53 mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wildtype"
                        }
                    ]
                },
                {
                    "exact_snippets": "TP53 wildtype AML",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed/Refractory to at least one prior therapy, one of which must have included a FLT-3 inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Relapsed/Refractory to at least one prior therapy",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        },
                        {
                            "requirement_type": "prior therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapy"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "one of which must have included a FLT-3 inhibitor",
                    "criterion": "prior therapy with FLT-3 inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* FLT3 mutation (FLT3-TKD or FLT3-ITD)",
            "criterions": [
                {
                    "exact_snippets": "FLT3 mutation (FLT3-TKD or FLT3-ITD)",
                    "criterion": "FLT3 mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "FLT3-TKD",
                                "FLT3-ITD"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG 0-2",
            "criterions": [
                {
                    "exact_snippets": "ECOG 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematologic, hepatic, and renal functions",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic...functions",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate...hepatic...functions",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate...renal functions",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Eligible for HSCT",
            "criterions": [
                {
                    "exact_snippets": "Eligible for HSCT",
                    "criterion": "HSCT eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with MDM2 antagonist therapies",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with MDM2 antagonist therapies",
                    "criterion": "prior treatment with MDM2 antagonist therapies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AML subtype 3",
            "criterions": [
                {
                    "exact_snippets": "AML subtype 3",
                    "criterion": "AML subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": "3"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}